aiwiki.page
English
Science / Biology / mevalonate-pathway

Mevalonate Pathway

The mevalonate pathway converts acetyl-CoA into five-carbon precursors used to produce sterols, membrane components, and many other essential isoprenoids.

37 keywords2 linked from12 not yet writtenWritten by AI
Acetyl-CoACholesterolMetabolismWaterEnantiomerMitochondrionAdenosine Tripho…Carbon DioxideMevalonate…

The mevalonate pathway is a sequence of biochemical reactions that converts acetyl-coenzyme A into isopentenyl diphosphate and dimethylallyl diphosphate, the five-carbon building blocks of isoprenoids. These precursors supply an exceptionally diverse family of compounds, including cholesterol, steroid hormones, respiratory quinones, and lipid groups that anchor proteins to membranes. The pathway is central to the metabolism of animals, fungi, archaea, and some bacteria, and it operates alongside a separate isoprenoid-producing pathway in plants.

Its name derives from mevalonate, the ionized form of mevalonic acid, a six-carbon intermediate formed by reduction of 3-hydroxy-3-methylglutaryl-coenzyme A. In the canonical pathway, three acetyl-CoA molecules provide the carbon for one five-carbon precursor; two NADPH molecules supply reducing power, and three ATP molecules support the reactions downstream of mevalonate. Alternative versions, especially in archaea, rearrange the later phosphorylation and decarboxylation steps.

The pathway connects basic carbon metabolism with membrane construction, intracellular signaling, and specialized natural-product synthesis. Its regulation is a major determinant of cellular sterol production, and its best-known enzyme, HMG-CoA reductase, is the molecular target of statin drugs. Its evolutionary diversity and its capacity to supply industrially valuable compounds also make it an important subject in comparative biochemistry and metabolic engineering.

Discovery and definition of the pathway

The mevalonate pathway emerged from investigations into the origin of cholesterol and other compounds built from repeating five-carbon units. Early twentieth-century work established the structural relationships among terpenes, but a structural “isoprene rule” did not explain how living cells produced or joined the relevant units. Isoprene itself is not the general metabolic building block. The active precursors are phosphorylated molecules whose chemistry allows controlled carbon–carbon bond formation.

During the 1940s and 1950s, experiments using labeled acetate established that the carbon skeleton of cholesterol originates from acetate-derived units. Work associated particularly with Konrad Bloch and Feodor Lynen connected acetyl-CoA metabolism to sterol biosynthesis and identified important intermediates and activated precursors. Bloch and Lynen shared the 1964 Nobel Prize in Physiology or Medicine for discoveries concerning the mechanism and regulation of cholesterol and fatty-acid metabolism. Their contributions placed cholesterol biosynthesis within a chemically explicit sequence rather than treating it as a series of inferred structural transformations.

Mevalonic acid was identified in the 1950s as a growth factor for certain lactobacilli and was subsequently shown to be an efficient precursor of cholesterol. These observations connected microbial nutritional requirements with animal sterol biosynthesis. Enzyme studies then established the sequence from acetyl-CoA through HMG-CoA and mevalonate to phosphorylated five-carbon products. The identification of isopentenyl diphosphate and its interconversion with dimethylallyl diphosphate explained how a common precursor pool could feed many chemically different end products.

The term mevalonate pathway usually refers specifically to the reactions producing these five-carbon precursors, not to every subsequent step of cholesterol or terpene formation. Cholesterol biosynthesis includes the mevalonate pathway but also requires prenyl-chain assembly, squalene formation, cyclization, and extensive sterol modification. Conversely, an organism can possess a mevalonate pathway without making cholesterol. Archaea, for example, use its products extensively to construct membrane lipids with chemistry fundamentally different from that of animal membranes.

A second route to the same five-carbon precursors was established during the 1990s: the methylerythritol phosphate pathway, commonly called the MEP or non-mevalonate pathway. Its recognition changed the interpretation of isoprenoid biosynthesis across organisms. The mevalonate route is therefore one of two major biological solutions to producing the shared precursors, rather than a universal pathway present in all cells.

Formation of mevalonate from acetyl-CoA

The first part of the pathway assembles three two-carbon acetyl units into a six-carbon intermediate and then reduces that intermediate to mevalonate. It begins when acetyl-CoA acetyltransferase, also called acetoacetyl-CoA thiolase, catalyzes the condensation of two acetyl-CoA molecules:

2 acetyl-CoA⇌acetoacetyl-CoA+CoA-SH.2\,\text{acetyl-CoA} \rightleftharpoons \text{acetoacetyl-CoA}+\text{CoA-SH}.

This reaction is a Claisen-type condensation. An enzyme-bound acetyl intermediate participates in formation of the new carbon–carbon bond. Because thiolases also function in other areas of metabolism, the occurrence of a thiolase alone does not demonstrate that an organism has a complete mevalonate pathway. Its physiological role depends on substrate supply, localization, and the presence of subsequent enzymes.

HMG-CoA synthase adds a third acetyl-CoA to acetoacetyl-CoA, producing 3-hydroxy-3-methylglutaryl-CoA, abbreviated HMG-CoA. The reaction consumes water and releases free coenzyme A. Its carbon skeleton now contains the six carbon atoms needed for mevalonate. In mammals, the cytosolic enzyme HMGCS1 supports sterol and isoprenoid synthesis, whereas the mitochondrial isoform HMGCS2 functions principally in ketogenesis. The shared intermediate does not imply that these processes draw from a single freely mixed HMG-CoA pool: compartmentation separates their principal physiological roles.

HMG-CoA reductase then converts the thioester group of HMG-CoA into the primary alcohol group of mevalonate. The enzyme uses two molecules of reduced nicotinamide adenine dinucleotide phosphate, NADPH, and releases CoA-SH. Chemically, reduction proceeds through two hydride-transfer events and a mevaldehyde intermediate. The reaction is strongly favorable under cellular conditions and is a major control point in animal cholesterol biosynthesis. The biologically used product is the RR enantiomer of mevalonate.

NADPH supplies reducing equivalents rather than the phosphate energy used later in the pathway. Its availability links isoprenoid production to the wider cellular redox economy, including the pentose phosphate pathway and other NADPH-generating reactions. Acetyl-CoA availability provides another connection to central metabolism. In many mammalian cells, citrate exported from the mitochondrion is cleaved by ATP-citrate lyase to furnish cytosolic acetyl-CoA; acetate activation can also contribute in particular physiological settings.

These first reactions are often called the upper mevalonate pathway, especially in engineering studies. The designation is operational rather than universal: it separates mevalonate production from the enzymes that convert mevalonate into activated isoprenoid precursors. Increasing upper-pathway activity without matching downstream capacity can cause intermediate accumulation rather than proportional increases in final-product synthesis.

Conversion of mevalonate into five-carbon precursors

In the canonical pathway of animals, fungi, and many other organisms, mevalonate undergoes two successive phosphorylations. Mevalonate kinase transfers a phosphate from ATP to the hydroxyl group at carbon 5, producing mevalonate 5-phosphate. Phosphomevalonate kinase adds a second phosphate to form mevalonate 5-diphosphate. These reactions create the diphosphate group retained in the final five-carbon precursor.

The next enzyme, mevalonate diphosphate decarboxylase, couples ATP consumption to the loss of the carboxyl carbon as carbon dioxide. Despite its abbreviated name, the enzyme performs more than a simple decarboxylation. It transiently phosphorylates the hydroxyl group at carbon 3, creating an unstable intermediate whose breakdown releases inorganic phosphate and carbon dioxide. The product is isopentenyl diphosphate, abbreviated IPP. Three ATP molecules have therefore been consumed between mevalonate and IPP: two establish the persistent diphosphate group, and one drives the elimination–decarboxylation chemistry.

The carbon accounting is straightforward:

3×C2⟶C6⟶C5+C1.3\times C_2 \longrightarrow C_6 \longrightarrow C_5+C_1.

Thus, five of the six carbon atoms supplied by three acetyl-CoA molecules remain in one IPP molecule, while the remaining carbon is released as carbon dioxide. For the canonical sequence, the direct requirements per IPP are three acetyl-CoA, two NADPH, and three ATP. This accounting excludes the costs of generating acetyl-CoA and NADPH and the additional reactions needed to make a particular end product.

IPP is interconverted with dimethylallyl diphosphate, or DMAPP, by isopentenyl diphosphate isomerase. The molecules have the same elemental composition but different double-bond positions. Their biochemical roles are complementary: DMAPP provides an allylic starter for many chain-building reactions, whereas IPP commonly provides the unit added during chain extension. Because the mevalonate sequence initially yields IPP, the isomerase is important for establishing a usable balance between the two precursors.

Two major isomerase families carry out this conversion. Type I enzymes use acid–base chemistry supported by metal ions. Type II enzymes use reduced flavin and are structurally unrelated to type I enzymes; the flavin participates in catalysis even though the overall reaction does not change the oxidation state of the substrate. This is an example of distinct enzyme architectures converging on the same metabolic transformation.

The term diphosphate is chemically preferable to the older pyrophosphate terminology, although IPP and DMAPP are still frequently expanded using either convention. Both names refer to the same biologically activated compounds, not to separate classes of precursor.

Distribution and alternative versions

The mevalonate pathway has a broad but uneven distribution across the tree of life. It supplies isoprenoid precursors in animals and fungi and is widespread among archaea. It also occurs in some bacteria, including organisms in which isoprenoid-derived lipid carriers are indispensable for cell-envelope construction. Many other bacteria instead use the MEP pathway. Pathway presence therefore cannot be inferred simply from whether an organism is prokaryotic or eukaryotic.

Comparative genomics initially created a puzzle in archaea. Many archaeal genomes encoded enzymes for converting acetyl-CoA to mevalonate but lacked recognizable genes for the complete canonical lower pathway. Biochemical work showed that these organisms were not necessarily missing isoprenoid synthesis; rather, several used alternative enzyme sequences. The upper reactions are relatively conserved, whereas the transformations between mevalonate and IPP exhibit substantial evolutionary variation.

One alternative, characterized in haloarchaea and some other organisms, phosphorylates mevalonate at carbon 5 and then decarboxylates mevalonate 5-phosphate to form isopentenyl phosphate. An isopentenyl phosphate kinase subsequently adds the second phosphate to produce IPP. Relative to the canonical sequence, the final stable phosphate addition occurs after, rather than before, carbon loss. The decarboxylation step remains coupled to ATP-dependent activation; rearranging the order of reactions does not mean that phosphorylation energy is unnecessary.

A different route, characterized in Thermoplasma acidophilum, begins the lower sequence by phosphorylating mevalonate at carbon 3. A second kinase generates mevalonate 3,5-bisphosphate, which is then decarboxylated to isopentenyl phosphate. Isopentenyl phosphate kinase again produces IPP. Additional archaeal variations include routes employing anhydromevalonate intermediates. These discoveries show that “the mevalonate pathway” describes a family of related biochemical solutions, not a single invariant list of enzymes.

Such variation is especially important when assigning functions from genome sequences. A protein annotated by similarity may differ in substrate preference from its nearest characterized relative, while a missing canonical enzyme may be replaced by an unrelated catalyst. Functional assignments are strongest when comparative sequence analysis is combined with purified-enzyme assays, metabolite identification, and genetic evidence. The distribution of pathway genes also reflects gene loss, duplication, and horizontal gene transfer, complicating reconstruction of the ancestral route.

The pathway’s antiquity is supported by its role in archaeal membrane formation and its broad biological distribution, but the exact sequence of evolutionary transitions remains under study. Present-day alternative routes should not automatically be arranged into a simple progression from primitive to advanced; each is a functioning metabolic system shaped by its lineage’s history.

Cellular compartmentation and the plant dual-pathway system

Location within the cell strongly influences what mevalonate-derived precursors become. In animal cells, the pathway is commonly described as cytosolic and endoplasmic-reticulum associated. HMG-CoA reductase is an integral protein of the endoplasmic reticulum, with its catalytic domain exposed to the cytosol. This arrangement places a major regulatory enzyme at a membrane system central to lipid synthesis while allowing access to soluble substrates and cofactors.

Descriptions of the pathway as exclusively cytosolic are nevertheless too simple. Peroxisomal localization or association has been reported for several enzymes in particular organisms and experimental systems. Localization can depend on species, isoform, tissue, and the methods used to identify targeting signals or visualize proteins. The physiologically relevant organization must therefore be established for the specific system rather than assumed from a universal compartment map.

Plants present a particularly important case because they possess both the mevalonate and MEP pathways. The mevalonate pathway operates predominantly in the cytosolic–endomembrane system and supplies much of the precursor used for sterols, many sesquiterpenes, and triterpenes. The MEP pathway operates in plastids, including chloroplasts, and commonly supplies carotenoids, the phytol chain of chlorophyll, and many mono- and diterpenes. These are dominant biosynthetic associations, not absolute boundaries applying to every compound in every plant.

The division is consistent with the evolutionary origin of plastids from bacteria and their retention of a bacterial-type precursor pathway. It also enables spatial regulation: a photosynthetic plastid can coordinate pigment production with its own metabolic state, while cytosolic isoprenoid synthesis responds to demands for membrane sterols and specialized defense compounds. Different tissues can therefore direct carbon into different isoprenoid classes even when their basic precursor chemistry is shared.

Exchange between the two precursor systems occurs, but its extent varies with species, development, and experimental conditions. Isotope-labeling studies and pathway-selective inhibitors have demonstrated cross-contributions to products that would otherwise be assigned to one compartment. These observations do not imply unrestricted equilibration of IPP and DMAPP across plastid membranes. The transported molecular species, transport capacity, and direction of net exchange must be considered separately.

Compartmentation also matters in fungi and engineered microorganisms. Moving enzymes or providing local precursor-generating modules can change access to substrates and competition among branches. Because diphosphorylated intermediates are charged and do not simply diffuse through lipid bilayers, physical proximity and membrane transport can limit product formation even when all required enzymes are present.

Products and physiological functions

The principal role of the mevalonate pathway is to supply activated five-carbon units, not to specify the final product. Downstream prenyltransferases determine initial chain length by joining an allylic substrate to IPP. Addition of one IPP to DMAPP yields the ten-carbon geranyl diphosphate; further addition yields the fifteen-carbon farnesyl diphosphate, or FPP. Addition of another unit produces twenty-carbon geranylgeranyl diphosphate, GGPP. Enzyme structure, substrate availability, and competing reactions determine which products accumulate.

FPP is a major branch point in animals and fungi. Two FPP molecules are joined to form squalene, which is oxidized and cyclized on the route to sterols. Animals produce cholesterol, while fungi commonly produce ergosterol. Cholesterol contributes to the physical organization of the cell membrane and is also a precursor of steroid hormones and bile acids. Sterol formation is thus a major destination for mevalonate-derived carbon, but it is only one of several essential branches.

FPP and GGPP also support protein prenylation, the covalent attachment of hydrophobic isoprenoid groups to selected proteins. Farnesyltransferase and geranylgeranyltransferases modify defined classes of substrates, often at cysteine residues near the protein’s carboxyl terminus. Many Ras-, Rho-, and Rab-family small GTPases require prenylation for appropriate membrane association and trafficking. The attached lipid does not by itself determine all aspects of localization, but its absence can disrupt signaling and intracellular transport.

Longer prenyl chains contribute to ubiquinone, also called coenzyme Q, which transfers electrons within the mitochondrial electron transport chain. They also form dolichols, whose phosphorylated derivatives act as lipid carriers during protein glycosylation in the endoplasmic reticulum. Bacteria that use the mevalonate pathway can channel its products into undecaprenyl phosphate, a carrier required for assembling cell-wall polymers such as peptidoglycan. These functions explain why blocking isoprenoid precursor production can affect processes far beyond sterol abundance.

In archaea, isoprenoid chains are central structural components of membrane lipids. Unlike the fatty-acid ester lipids typical of bacteria and eukaryotes, characteristic archaeal lipids contain ether-linked isoprenoid chains attached to glycerol backbones of different stereochemistry. Geranylgeranyl-derived chains can be reduced and incorporated into membrane-spanning or membrane-forming structures. This creates a direct connection between mevalonate metabolism and the distinctive chemistry of archaeal cellular organization.

Plants and fungi additionally use mevalonate-derived precursors for numerous specialized metabolites, including defensive sesquiterpenes and triterpenes. The same precursor pool can therefore sustain indispensable housekeeping functions and highly lineage-specific ecological traits. Diversification occurs mainly through downstream chain-assembly, cyclization, oxidation, and conjugation reactions rather than through a different fundamental five-carbon building block.

Regulation of flux and sterol homeostasis

Regulation of the mevalonate pathway must balance multiple demands. Excessive sterol accumulation can disturb membrane function, but excessive suppression of the pathway also limits nonsterol products needed for protein modification, glycosylation, and respiration. Control is consequently distributed across transcription, enzyme degradation, reversible modification, precursor availability, and competition among downstream branches. HMG-CoA reductase is a particularly important control point, but calling it the universally rate-limiting enzyme obscures the dependence of flux control on cell type and physiological state.

In mammals, a central transcriptional mechanism involves sterol regulatory element-binding proteins, or SREBPs. SREBP-2 is especially important in cholesterol homeostasis. It is synthesized as an endoplasmic-reticulum membrane protein associated with SCAP, a sterol-sensing escort protein. When sterol availability is low, the complex can move to the Golgi apparatus, where sequential proteolysis releases the SREBP transcription-factor domain. This domain enters the nucleus and increases expression of genes involved in cholesterol synthesis and uptake, including HMG-CoA reductase and the LDL receptor.

When sterol levels are sufficient, interactions involving SCAP and INSIG proteins retain the complex in the endoplasmic reticulum. This reduces production of the active transcription factor. The resulting feedback system couples synthesis and uptake rather than regulating biosynthesis in isolation. It also explains why inhibition of cholesterol synthesis can produce compensatory increases in the expression of pathway enzymes.

HMG-CoA reductase abundance is additionally regulated through endoplasmic-reticulum-associated protein degradation. Particular sterol signals promote its association with INSIG proteins, facilitating ubiquitination and proteasomal turnover. Nonsterol mevalonate-derived signals also contribute to this control system. Transcriptional and degradation mechanisms operate on different timescales and can act together: a cell can both reduce new enzyme production and remove enzyme already present.

Reversible phosphorylation supplies another layer of control. AMP-activated protein kinase, a sensor of cellular energy status, can phosphorylate and inhibit mammalian HMG-CoA reductase. This links an energetically expensive biosynthetic process to the availability of cellular energy. Other pathway enzymes also have regulatory properties; mevalonate kinase, for example, can be inhibited by downstream prenyl diphosphates, although inhibitor sensitivity differs among organisms and enzyme forms.

Whole-pathway flux cannot be inferred reliably from HMG-CoA reductase messenger RNA alone. Protein abundance, catalytic state, acetyl-CoA and NADPH supply, downstream consumption, and metabolite transport all intervene between gene expression and product formation. In fungi and plants, regulatory arrangements share some general principles with the mammalian system but differ in their transcription factors, enzyme isoforms, and responses to environmental signals.

Pharmacology and inherited disorders

The best-known pharmacological intervention in the pathway is inhibition of HMG-CoA reductase by statins. These compounds occupy the enzyme’s catalytic region and compete with its physiological substrate. Compactin, also called mevastatin, was identified by Akira Endo and colleagues in the 1970s during studies of fungal metabolites. Lovastatin became the first statin approved in the United States, in 1987. Subsequent drugs expanded the class while retaining the same principal biochemical target.

Inhibition reduces hepatic cholesterol synthesis and activates compensatory cholesterol-homeostatic responses, including increased LDL-receptor expression. Greater receptor-mediated clearance lowers circulating LDL cholesterol. The pathway mechanism therefore involves both an intracellular biosynthetic block and an organism-level change in lipoprotein handling. Statins also reduce the availability of precursors for nonsterol branches, but the established clinical benefits of LDL lowering should be distinguished from broader mechanistic effects observed in experimental systems.

Other drugs act farther downstream. Nitrogen-containing bisphosphonates, including alendronate and zoledronate, inhibit farnesyl diphosphate synthase. Their affinity for bone mineral concentrates their action at sites of bone resorption. In osteoclasts, reduced production of prenyl diphosphates interferes with protein prenylation and with cellular functions required for resorption. This mechanism differs from that of non-nitrogen-containing bisphosphonates, which act primarily through formation of cytotoxic ATP analogues.

Inherited disruption demonstrates the pathway’s importance independently of pharmacological inhibition. Mevalonate kinase deficiency is an autosomal recessive disorder caused by pathogenic variants in the MVK gene. Its clinical spectrum includes recurrent inflammatory episodes and, in more severe forms, developmental and neurological abnormalities associated with mevalonic aciduria. The historical term hyperimmunoglobulinemia D syndrome describes part of this spectrum, but elevated immunoglobulin D is not a universal feature and does not define the molecular defect.

The inflammatory consequences of mevalonate kinase deficiency involve more than accumulation of its immediate substrate. Experimental studies connect reduced downstream isoprenoid availability, impaired protein geranylgeranylation, and altered regulation of innate immune signaling. This illustrates why a defect in a pathway associated popularly with cholesterol can produce a prominent inflammatory phenotype. The exact contribution of individual downstream branches depends on the biological context.

The pathway is also investigated in cancer biology and antimicrobial research. Tumor cells can alter mevalonate metabolism, while some pathogens depend on a mevalonate route absent from closely related organisms. Such observations identify potential vulnerabilities but do not establish that pathway inhibition is effective against every tumor or infection. Enzyme selectivity, tissue exposure, alternative precursor acquisition, and the essential requirements of host cells all affect whether a biochemical target can become a useful therapy.

Experimental analysis and metabolic engineering

The pathway is studied by combining biochemical assays, genetics, metabolite measurements, and isotope tracing. Purified-enzyme experiments establish substrate specificity, catalytic requirements, and kinetic behavior. HMG-CoA reductase activity can be followed through NADPH consumption, while kinase and decarboxylase reactions can be examined by measuring nucleotide conversion or directly identifying products. Coupled assays require controls because a signal from an auxiliary enzyme does not by itself prove the identity of the pathway intermediate.

Mass spectrometry, often combined with liquid chromatography, enables measurement of mevalonate and many prenyl metabolites. These compounds present analytical difficulties: diphosphates are highly polar, can be chemically labile, and may occur at low concentrations. Extraction recovery, rapid metabolic quenching, and suitable internal standards are therefore important. A low steady-state concentration does not necessarily imply low pathway activity, because a rapidly produced intermediate may also be rapidly consumed.

Stable-isotope labeling provides information about carbon flow rather than abundance alone. Labeled acetate, glucose, or other carbon sources can reveal the contributions of precursor pools to downstream products. In plants, characteristic labeling patterns have helped distinguish mevalonate-derived from MEP-derived carbon. Interpretation requires accounting for central-metabolic rearrangements and exchange between compartments; the label in a final terpene is not always a direct record of a single isolated pathway.

Metabolic engineering uses the pathway as a modular source of IPP and DMAPP. Saccharomyces cerevisiae possesses a native mevalonate pathway, whereas commonly used Escherichia coli strains normally rely on the MEP route and can be engineered to carry a heterologous mevalonate module. Strategies include increasing acetyl-CoA supply, strengthening NADPH generation, modifying HMG-CoA reductase regulation, and balancing expression of upper- and lower-pathway enzymes. Introducing a truncated, catalytically active reductase can reduce some native regulatory constraints, although its effect depends on the strain and production system.

A prominent demonstration was the production of artemisinic acid in engineered yeast, reported in 2006, followed by industrial development of semisynthetic artemisinin manufacture. The engineered cells supplied elevated isoprenoid flux to amorphadiene synthesis and then used introduced oxidation enzymes to produce artemisinic acid. Chemical conversion supplied the final antimalarial compound. This example illustrates both the reach and the limits of pathway engineering: enhanced precursor formation was necessary, but downstream enzyme performance and chemical processing were equally important.

Engineering challenges include intermediate toxicity, diversion into essential native products, cofactor limitations, and the cellular burden of expressing multiple enzymes. Excess IPP or prenyl diphosphates can impair growth, while suppressing sterol synthesis too strongly can compromise membrane function. Dynamic control, enzyme balancing, compartment targeting, and two-stage cultivation are consequently used to separate biomass formation from intensive product synthesis. Performance is assessed through product titer, yield from feedstock, and volumetric productivity, because improving any one of these measures does not guarantee improvement in the others.